PMS1 homolog 2, mismatch repair system component pseudogene 1Genealiases: []
Q-omics provides the consensus-scored PMS2P1 profile across patient tissues and cancer cell-line models. PMS2P1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, PMS2P1 is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, PMS2P1 RNA expression shows 19,359 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KICH, KIRC, and ACC as cancer lineages where PMS2P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PMS2P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PMS2P1 survival associations across molecular data types. PMS2P1 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PMS2P1 RNA expression–survival associations across cancer types. High PMS2P1 expression shows unfavorable associations in KICH, UVM, LGG, UCEC and CESC, but favorable associations in BRCA. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for PMS2P1 RNA expression.
This table summarizes PMS2P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for PMS2P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PMS2P1 shows higher tumor expression in KIRC, HNSC, LIHC, COAD, LUAD and LUSC. The KIRC box plot shows higher PMS2P1 RNA expression in tumor versus normal tissue (log2 FC = +0.507, t-test p < 0.001).
This table shows molecular features associated with PMS2P1 in patient tissues and cancer cell lines. In patient samples, PMS2P1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, PMS2P1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and NCI60_ALL.
